darunavir teva 600mg film-coated tablets
teva b.v. - darunavir - film-coated tablet - 600 milligram(s) - protease inhibitors; darunavir
darunavir rowex 75 mg film-coated tablets
rowex ltd - darunavir - film-coated tablet - 75 milligram(s) - protease inhibitors; darunavir
darunavir rowex 400 mg film-coated tablets
rowex ltd - darunavir - film-coated tablet - 400 milligram(s) - protease inhibitors; darunavir
darunavir rowex 600 mg film-coated tablets
rowex ltd - darunavir - film-coated tablet - 600 milligram(s) - protease inhibitors; darunavir
darunavir accord 600 mg film-coated tablets
accord healthcare ireland ltd. - darunavir - film-coated tablet - 600 milligram(s) - protease inhibitors; darunavir
darunavir accord 800 mg film-coated tablets
accord healthcare ireland ltd. - darunavir - film-coated tablet - 800 milligram(s) - protease inhibitors; darunavir
prezista 400 mg
j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 400 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.
prezista 600 mg
j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 600 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.
norvir
abbvie deutschland gmbh co. kg - ritonavir - hiv infections - antivirals for systemic use, - ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv-1-infected patients (adults and children of two years of age and older).,
viracept
roche registration ltd. - nelfinavir - hiv infections - antivirals for systemic use - viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (hiv-1)-infected adults, adolescents and children of three years of age and older.in protease-inhibitor (pi)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.